[Clinical significance of the novel tumor marker CYFRA21-1 in patients with esophageal cancer].
OBJECTIVE
To study the clinical significance of the novel tumor marker--CYFRA21-1 in patients with esophageal cancer.


METHODS
The CYFRA21-1 level in serum of 84 patients with a definite diagnosis of esophageal cancer was examined 10 days before and after operation by ELISA. A 3 years' follow-up was conducted to the survival of patients.


RESULTS
(1) The CYFRA21-1 level was > 3.3 ng/ml in 72.6% of the patients (61/84). (2) The serum CYFRA21-1 level decreased significantly after operation in patients at stage III or with high differentiation (P < 0.05). (3) The difference between pre- and post-operative serum CYFRA21-1 levels was statistically significant in patients who had undegone radical operation, and was not in patients who had undergone palliative operation. (4) In addition to stage (P < 0.05) and type of operation (P < 0.05), the difference of CYFRA21-1 level before and after operationwas closely related to the prognosis (P < 0.05).


CONCLUSIONS
CYFRA21-1 is a useful marker in diagnosis and prediction of prognosis of esophageal cancer.
Wang
T
T
Department of Thoracic Surgery, Peking Union Hospital, Peking Union Medical Collage, Beijing 100730, China.
Zhang
W
W
Liu
Y
Y
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D004938:Esophageal Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods; D011379:Prognosis; D012984:Software; D016019:Survival Analysis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins